Skip to main content
SpringerLink
Log in

Pregnancy Morbidity Associated with Thrombophilias: Late Placenta-Mediated Obstetric Complications

  • Chapter
Disorders of Thrombosis and Hemostasis in Pregnancy

  • 1254 Accesses

Abstract

Late pregnancy complications such as severe pre-eclampsia and placental insufficiency at less than 34 weeks gestation are relatively common, as are thrombophilic risk factors, with these risk factors associated with an increased risk of venous thromboembolism during pregnancy. This chapter will focus on associations between heritable thrombophilias and antiphospholipid antibodies with late placenta-mediated complications and the management of affected women.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157:47–58.

    CAS  PubMed  Google Scholar 

  2. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.

    CAS  PubMed  Google Scholar 

  3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

    CAS  PubMed  Google Scholar 

  4. Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol. 1992;80(1):132–7.

    CAS  PubMed  Google Scholar 

  5. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16(2):153–68.

    PubMed  Google Scholar 

  6. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29:125–30.

    CAS  PubMed  Google Scholar 

  7. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 1986;68(4):881–5.

    CAS  PubMed  Google Scholar 

  8. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90(3):725–7.

    CAS  PubMed  Google Scholar 

  9. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost. 1984;52(2):176–82.

    CAS  PubMed  Google Scholar 

  10. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987;69(2):460–6.

    CAS  PubMed  Google Scholar 

  11. Giavarina D, Mezzena G, Dorizzi RM, Soffiati G. Reference interval of D-dimer in pregnant women. Clin Biochem. 2001;34(4):331–3.

    CAS  PubMed  Google Scholar 

  12. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131–6.

    CAS  PubMed  Google Scholar 

  13. Arachchillage DR, Machin SJ, Mackie IJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2015;113(1):13–9.

    PubMed  Google Scholar 

  14. Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan E, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008;6:1693–6.

    CAS  PubMed  Google Scholar 

  15. Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus. 2013;22:18–25.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Mekinian A, Loire-Berson P, Nicaise-Roland P, Lachassinne E, Stirnemann J, Boffa MC, et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol. 2012;94:222–6.

    PubMed  Google Scholar 

  17. Alijotas-Reig J, Ferrer-Oliveras R. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus. 2012;21:766–8.

    CAS  PubMed  Google Scholar 

  18. Out HJ, Bruinse HW, Christiaens GC, van Vliet M, De Groot PG, Nieuwenhuis HK, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992;167(1):26–32.

    CAS  PubMed  Google Scholar 

  19. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol. 1982;142:829–34.

    PubMed  Google Scholar 

  20. Hanly JG, Gladman DD, Rose TH, Laskin CA, Urowitz MB. Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum. 1988;31:358–66.

    CAS  PubMed  Google Scholar 

  21. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intrauterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol. 1991;41:179–86.

    CAS  PubMed  Google Scholar 

  22. Di SN, Luigi MP, Marco D, Fiorella DN, Silvia D, Clara DM, et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci. 2007;1108:505–14.

    Google Scholar 

  23. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome – a possible thrombogenic mechanism. N Engl J Med. 1997;337(3):154–60.

    CAS  PubMed  Google Scholar 

  24. Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost. 2012;107:423–9.

    CAS  PubMed  Google Scholar 

  25. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol. 2008;77:51–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:1433–43.

    PubMed  Google Scholar 

  27. Abou-Nasser K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies with preeclampsia: a systematic review and meta-analysis. Thromb Res. 2011;128:77–85.

    Google Scholar 

  28. Chauleur C, Galanaud JP, Alonso S, Cochery-Nouvellon E, Balducchi JP, Marès P, et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost. 2010;8(4):699–706.

    CAS  PubMed  Google Scholar 

  29. Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. CMAJ. 2002;167(1):48–54.

    PubMed Central  PubMed  Google Scholar 

  30. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133–4.

    CAS  PubMed  Google Scholar 

  31. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, Regan L. Factor V. Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod. 2001;16(5):961–5.

    Google Scholar 

  32. Zoller B, de Garcia FP, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica. 1999;84(1):59–70.

    CAS  PubMed  Google Scholar 

  33. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemostas. 1998;79:706–8.

    CAS  Google Scholar 

  34. Conard J, Horellou MH, Van DP, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990;63(2):319–20.

    CAS  PubMed  Google Scholar 

  35. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol. 2002;99(2):333–41.

    PubMed  Google Scholar 

  36. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171–96.

    CAS  PubMed  Google Scholar 

  37. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med. 2010;7(6):e1000292.

    PubMed Central  PubMed  Google Scholar 

  38. Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, Carson N, Carrier M, Rennicks White R, Shachkina S, Wen SW. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost. 2014;12(4):469–78.

    CAS  PubMed  Google Scholar 

  39. Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol. 2001;98(6):1041–4.

    CAS  PubMed  Google Scholar 

  40. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod. 2000;15(8):1830–3.

    CAS  PubMed  Google Scholar 

  41. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intrauterine growth restriction in women with and without thrombophilia. Placenta. 2002;23(4):337–42.

    CAS  PubMed  Google Scholar 

  42. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med. 1998;7(6):277–86.

    CAS  PubMed  Google Scholar 

  43. Hack M, Flannery DJ, Schluchter M, Cartar L, Borawski E, Klein N. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med. 2002;346(3):149–57.

    PubMed  Google Scholar 

  44. Resnik R. Intrauterine growth restriction. Obstet Gynecol. 2002;99(3):490–6.

    PubMed  Google Scholar 

  45. Barker DJ. The fetal and infant origins of adult disease. BMJ. 1990;301(6761):1111.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. Haematologica. 2002;87(2):177–81.

    CAS  PubMed  Google Scholar 

  47. von Kries R, Junker R, Oberle D, Kosch A, Nowak-Gottl U. Foetal growth restriction in children with prothrombotic risk factors. Thromb Haemost. 2001;86(4):1012–6.

    Google Scholar 

  48. Sabadell J, Casellas M, Alijotas-Reig J, Arellano-Rodrigo E, Cabero L. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):47–51.

    CAS  PubMed  Google Scholar 

  49. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996;75(3):387–8.

    CAS  PubMed  Google Scholar 

  50. Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol. 1997;177(2):402–5.

    CAS  PubMed  Google Scholar 

  51. de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol. 1997;104(11):1248–54.

    PubMed  Google Scholar 

  52. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol. 1998;179(6 Pt 1):1565–7.

    CAS  PubMed  Google Scholar 

  53. Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost. 2004;91(4):700–11.

    CAS  PubMed  Google Scholar 

  54. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens. 2003;21(7):1221–8.

    CAS  PubMed  Google Scholar 

  55. Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol. 2005;105(1):182–92.

    PubMed  Google Scholar 

  56. Muetze S, Leeners B, Ortlepp JR, Kuse S, Tag CG, Weiskirchen R, et al. Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. Acta Obstet Gynecol Scand. 2008;87(6):635–42.

    CAS  PubMed  Google Scholar 

  57. Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JI. Thrombophilias and adverse pregnancy outcome – a confounded problem! Thromb Haemost. 2008;99(1):77–85.

    CAS  PubMed  Google Scholar 

  58. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000;71(4):962–8.

    CAS  PubMed  Google Scholar 

  59. Morgan JA, Bombell S, McGuire W. Association of plasminogen activator inhibitor-type 1 (−675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One. 2013;8(2):e56907. doi:10.1371/journal.pone.0056907. Epub 2013 Feb 15.

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand. 2000;79(11):963–7.

    CAS  PubMed  Google Scholar 

  61. Higgins JR, Kaiser T, Moses EK, North R, Brennecke SP. Prothrombin G20210A mutation: is it associated with pre-eclampsia? Gynecol Obstet Invest. 2000;50(4):254–7.

    CAS  PubMed  Google Scholar 

  62. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost. 2002;87(5):779–85.

    CAS  PubMed  Google Scholar 

  63. Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, et al. Case–control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent–the Nimes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost. 1999;81(6):891–9.

    CAS  PubMed  Google Scholar 

  64. Agorastos T, Karavida A, Lambropoulos A, Constantinidis T, Tzitzimikas S, Chrisafi S, et al. Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal Med. 2002;12(4):267–73.

    CAS  PubMed  Google Scholar 

  65. Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG. 2002;109(12):1373–6.

    PubMed  Google Scholar 

  66. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol. 2002;99(5 Pt 1):684–7.

    PubMed  Google Scholar 

  67. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340(1):9–13.

    CAS  PubMed  Google Scholar 

  68. Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica. 2001;86(4):428–31.

    CAS  PubMed  Google Scholar 

  69. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med. 2002;347(1):19–25.

    CAS  PubMed  Google Scholar 

  70. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005;192(3):694–708.

    CAS  PubMed  Google Scholar 

  71. Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol. 2008;140(2):236–40.

    PubMed  Google Scholar 

  72. Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost. 2008;6(11):1869–75.

    CAS  PubMed  Google Scholar 

  73. McCowan LM, Craigie S, Taylor RS, Ward C, McLintock C, North RA. Inherited thrombophilias are not increased in “idiopathic” small-for-gestational-age pregnancies. Am J Obstet Gynecol. 2003;188(4):981–5.

    PubMed  Google Scholar 

  74. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol. 2009;200(1):46.e1–5.

    Google Scholar 

  75. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997;77(6):1052–4.

    CAS  PubMed  Google Scholar 

  76. Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T, et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension. 2005;46(6):1270–4.

    CAS  PubMed  Google Scholar 

  77. Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest Jr J, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol. 2009;200(2):151–9.

    PubMed  Google Scholar 

  78. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Scianname N, Montanaro S, et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost. 1999;81(3):349–52.

    CAS  PubMed  Google Scholar 

  79. Murphy RP, Donoghue C, Nallen RJ, D’Mello M, Regan C, Whitehead AS, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol. 2000;20(1):266–70.

    CAS  PubMed  Google Scholar 

  80. Benedetto C, Marozio L, Salton L, Maula V, Chieppa G, Massobrio M. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand. 2002;81(12):1095–100.

    PubMed  Google Scholar 

  81. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM. 2006;99(5):289–98.

    CAS  PubMed  Google Scholar 

  82. Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy com-plications. Obstet Gynecol. 2001;97(5 Pt 1):753–9.

    CAS  PubMed  Google Scholar 

  83. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost. 1999;81(4):532–7.

    CAS  PubMed  Google Scholar 

  84. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, et al. Preeclampsia and genetic risk factors for thrombosis: a case–control study. Am J Obstet Gynecol. 1999;181(4):975–80.

    PubMed  Google Scholar 

  85. van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG. 2000;107(6):785–91.

    PubMed  Google Scholar 

  86. Prochazka M, Happach C, Marsal K, Dahlback B, Lindqvist PG. Factor V Leiden in pregnancies complicated by placental abruption. BJOG. 2003;110(5):462–6.

    CAS  PubMed  Google Scholar 

  87. Prochazka M, Lubusky M, Slavik L, Hrachovec P, Zielina P, Kudela M, et al. Frequency of selected thrombophilias in women with placental abruption. Aust N Z J Obstet Gynaecol. 2007;47(4):297–301.

    PubMed  Google Scholar 

  88. Facco F, You W, Grobman W. Genetic thrombophilias and intrauterine growth restriction: a meta-analysis. Obstet Gynecol. 2009;113(6):1206–16.

    PubMed  Google Scholar 

  89. Nath CA, Ananth CV, DeMarco C, Vintzileos AM. Low birthweight in relation to placental abruption and maternal thrombophilia status. Am J Obstet Gynecol. 2008;198(3):293–5.

    PubMed Central  PubMed  Google Scholar 

  90. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol. 2002;101(1):6–14.

    PubMed  Google Scholar 

  91. Ananth CV, Nath CA, Philipp C, New Jersey Placental Abruption Study. The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C. J Matern Fetal Neonatal Med. 2010;23(12):1377–83.

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996;348(9032):913–6.

    CAS  PubMed  Google Scholar 

  93. Pasquier E, Bohec C, Mottier D, Jaffuel S, Mercier B, Ferec C, et al. Inherited thrombophilias and unexplained pregnancy loss: an incident case–control study. J Thromb Haemost. 2009;7(2):306–11.

    CAS  PubMed  Google Scholar 

  94. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361(9361):901–8.

    PubMed  Google Scholar 

  95. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000;343(14):1015–8.

    CAS  PubMed  Google Scholar 

  96. Cleary-Goldman J, Bettes B, Robinson JN, Norwitz E, Schulkin J. Thrombophilia and the obstetric patient. Obstet Gynecol. 2007;110(3):669–74.

    PubMed  Google Scholar 

  97. Rodger MA, Carrier M, Keely E, Karovitch A, Nimrod C, Walker M, et al. The management of thrombophilia during pregnancy: a Canadian survey. J Obstet Gynaecol Can. 2002;24(12):946–52.

    PubMed  Google Scholar 

  98. Walker ID, Kujovich JL, Greer IA, Rey E, David M, Salmon JE, et al. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost. 2005;3(4):778–93.

    CAS  PubMed  Google Scholar 

  99. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005;3(2):227–9.

    CAS  PubMed  Google Scholar 

  100. Grandone E, Brancaccio V, Colaizzo D, Scianname N, Pavone G, Di MG, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002;78(2):371–5.

    PubMed  Google Scholar 

  101. Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001;20(1):35–44.

    CAS  PubMed  Google Scholar 

  102. Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol. 1998;80(1):49–54.

    CAS  PubMed  Google Scholar 

  103. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695–9.

    CAS  PubMed  Google Scholar 

  104. Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104(4):771–9.

    CAS  PubMed  Google Scholar 

  105. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  106. Goel N, et al. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12:CR132–6.

    CAS  PubMed  Google Scholar 

  107. Mak A, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology. 2010;49:281–8.

    CAS  PubMed  Google Scholar 

  108. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S–736.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. de Jesus GR, Agmon-Levin N, Andrade CA, Andreoli L, Chighizola CB, Porter TF, Salmon J, Silver RM, Tincani A, Branch DW. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13(8):795–813.

    PubMed  Google Scholar 

  110. Kaandorp S, Di NM, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent mis-carriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2009;(1):CD004734.

    Google Scholar 

  111. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, et al. Preeclampsia and genetic risk factors for thrombosis: a case–control study. Am J Obstet Gynecol. 1999;181(4):975–80.

    PubMed  Google Scholar 

  112. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol. 1995;35(4):357–62.

    CAS  PubMed  Google Scholar 

  113. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322(7282):329–33.

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83(5):693–7.

    CAS  PubMed  Google Scholar 

  115. Leeda M, Riyazi N, de Vries JI, Jakobs C, van Geijn HP, Dekker GA. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol. 1998;179(1):135–9.

    CAS  PubMed  Google Scholar 

  116. de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH, FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10(1):64–72. doi:10.1111/j.1538-7836.2011.04553.x.

    PubMed  Google Scholar 

  117. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al.; for the TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014. pii: S0140-6736(14)60793-5. doi: 10.1016/S0140-6736(14)60793-5. [Epub ahead of print].

  118. Kingdom JC, Walker M, Proctor LK, Keating S, Shah PS, McLeod A, et al. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost. 2011;9(8):1483–92.

    CAS  PubMed  Google Scholar 

  119. Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, de Vries JI, Gris JC, Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123(6):822–8. doi:10.1182/blood-2013-01-478958. Epub 2013 Dec 19.

    CAS  PubMed  Google Scholar 

  120. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209–20.

    PubMed  Google Scholar 

  121. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7(1):58–64.

    CAS  PubMed  Google Scholar 

  122. National Collaborating Centre for Women’s and Children’s Health. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press; 2010.

    Google Scholar 

  123. Franchi F, Biguzzi E, Cetin I, Facchetti F, Radaelli T, Bozzo M, et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol. 2001;114(3):641–6.

    CAS  PubMed  Google Scholar 

  124. Nakabayashi M, Yamamoto S, Suzuki K. Analysis of thrombomodulin gene polymorphism in women with severe early-onset preeclampsia. Semin Thromb Hemost. 1999;25(5):473–9.

    CAS  PubMed  Google Scholar 

  125. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, Wolf M, Mairovitz V, Hugel B, et al. Circulating pro-coagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost. 2001;85(1):18–21.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Women’s Health Services, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, Stadium Road, London, SE18 4QH, UK

    Sukrutha Veerareddy BSc, MBBS, MRCOG, PhD

  2. Department of Haematology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK

    Katherine Clesham MB ChB, MRCP, FRCPath

  3. Department of Haematology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, UK

    Hannah Cohen MB ChB, MD, FCRP, FRCPath

  4. Institute for Women’s Health, University College London Hospitals NHS Foundation Trust, 2nd floor, Medical School Building, 72 Huntley St, London, WC1E 6AU, UK

    Donald Peebles MA, MD, FRCOG

Authors
  1. Sukrutha Veerareddy BSc, MBBS, MRCOG, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine Clesham MB ChB, MRCP, FRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hannah Cohen MB ChB, MD, FCRP, FRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donald Peebles MA, MD, FRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald Peebles MA, MD, FRCOG .

Editor information

Editors and Affiliations

  1. Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Hannah Cohen

  2. Institute for Women's Health, University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Patrick O'Brien

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Veerareddy, S., Clesham, K., Cohen, H., Peebles, D. (2015). Pregnancy Morbidity Associated with Thrombophilias: Late Placenta-Mediated Obstetric Complications. In: Cohen, H., O'Brien, P. (eds) Disorders of Thrombosis and Hemostasis in Pregnancy. Springer, Cham. https://doi.org/10.1007/978-3-319-15120-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-15120-5_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-15119-9

  • Online ISBN: 978-3-319-15120-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation